ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.01 per share
Symbol
ENTA on Nasdaq
Shares outstanding
27,767,902
Price per share
$15.77
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
18,990,940
Total reported value
$227,099,816
% of total 13F portfolios
0%
Share change
+569,289
Value change
+$8,890,509
Number of holders
119
Price from insider filings
$15.77
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 12% $41,823,994 3,494,068 JANUS HENDERSON GROUP PLC 31 Oct 2025
Farallon Capital Partners, L.P. 9.9% $9,782,336 2,108,262 Dapice Joshua J. 31 Dec 2024
Luly Jay R. 7.7% $7,904,778 1,703,616 Jay R. Luly, Ph.D. 12 Feb 2025
BlackRock, Inc. 7.8% $7,764,961 1,673,483 BlackRock, Inc. 31 Mar 2025
Deep Track Capital, LP 5.3% $17,769,621 1,484,513 Deep Track Capital, LP 02 Oct 2025
INTEGRATED CORE STRATEGIES (US) LLC 4.1% -34% $13,627,653 -$2,918,154 1,138,484 -18% Millennium Management LLC 30 Sep 2025

As of 30 Sep 2025, 119 institutional investors reported holding 18,990,940 shares of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA). This represents 68% of the company’s total 27,767,902 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) together control 61% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FARALLON CAPITAL MANAGEMENT LLC 7.6% 2,122,262 0% 0.14% $25,403,476
Krensavage Asset Management, LLC 7.6% 2,114,444 0% 11% $25,310,000
JANUS HENDERSON GROUP PLC 7% 1,946,914 +272% 0.01% $23,285,091
VANGUARD GROUP INC 7% 1,938,829 -1.9% 0% $23,207,783
BlackRock, Inc. 6.6% 1,832,980 -0.75% 0% $21,940,770
MILLENNIUM MANAGEMENT LLC 3.4% 948,084 -35% 0.01% $11,348,565
ACADIAN ASSET MANAGEMENT LLC 3.1% 867,037 0% 0.02% $10,374,000
Commodore Capital LP 2.9% 800,000 0.47% $9,576,000
GEODE CAPITAL MANAGEMENT, LLC 1.8% 493,194 +1.5% 0% $5,904,427
RENAISSANCE TECHNOLOGIES LLC 1.7% 479,600 +2.2% 0.01% $5,740,812
STATE STREET CORP 1.7% 471,992 +0.37% 0% $5,649,744
Stonepine Capital Management, LLC 1.1% 305,000 -50% 3% $3,650,850
Point72 Asset Management, L.P. 1.1% 300,000 0.01% $3,590,999
MORGAN STANLEY 1% 282,631 -1.4% 0% $3,383,104
MARSHALL WACE, LLP 0.99% 275,389 -68% 0% $3,296,407
DIMENSIONAL FUND ADVISORS LP 0.97% 270,068 -2.7% 0% $3,235,361
AQR CAPITAL MANAGEMENT LLC 0.82% 226,845 -43% 0% $2,715,336
D. E. Shaw & Co., Inc. 0.81% 225,744 -20% 0% $2,702,156
NORTHERN TRUST CORP 0.71% 195,896 -22% 0% $2,344,875
JACOBS LEVY EQUITY MANAGEMENT, INC 0.61% 169,048 -12% 0.01% $2,023,505
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.6% 166,547 +1.2% 0% $1,993,568
GOLDMAN SACHS GROUP INC 0.6% 166,433 +43% 0% $1,992,203
Nuveen, LLC 0.59% 164,760 +267% 0% $1,972,177
Trexquant Investment LP 0.46% 127,363 -52% 0.02% $1,524,535
TANG CAPITAL MANAGEMENT LLC 0.46% 126,655 0% 0.06% $1,516,060

Institutional Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 60,338 $928,051 -$139,191 $15.77 6
2025 Q3 18,990,940 $227,099,816 +$8,890,509 $11.97 119
2025 Q2 18,415,660 $139,219,060 -$1,129,334 $7.56 104
2025 Q1 18,625,766 $102,810,410 -$7,313,394 $5.52 108
2024 Q4 19,907,432 $114,464,893 -$17,468,477 $5.75 105
2024 Q3 21,189,161 $219,535,311 -$10,717,659 $10.36 109
2024 Q2 22,131,926 $287,039,605 -$4,639,010 $12.97 99
2024 Q1 22,403,789 $391,166,989 +$30,052,871 $17.46 105
2023 Q4 174,304 $1,640,201 +$52,696 $9.41 3
2023 Q3 20,049,610 $223,947,000 -$5,477,238 $11.17 128
2023 Q2 19,691,658 $421,397,433 -$18,003,727 $21.40 126
2023 Q1 19,742,193 $798,226,423 +$23,679,035 $40.44 141
2022 Q4 19,133,773 $890,118,458 -$45,122,440 $46.52 143
2022 Q3 19,590,518 $1,016,071,993 -$25,554,700 $51.87 151
2022 Q2 20,157,248 $952,826,115 +$14,829,172 $47.27 148
2022 Q1 19,549,988 $1,390,886,185 +$57,817,680 $71.18 160
2021 Q4 18,759,120 $1,401,919,269 -$51,479,805 $74.78 170
2021 Q3 19,365,073 $1,100,212,074 +$34,210,945 $56.81 139
2021 Q2 18,807,443 $827,826,567 -$26,870,700 $44.01 147
2021 Q1 19,411,772 $955,770,887 +$8,025,561 $49.32 144
2020 Q4 19,204,942 $808,636,243 +$16,459,112 $42.10 146
2020 Q3 18,756,229 $858,512,102 +$27,248,495 $45.78 166
2020 Q2 18,231,181 $915,245,733 +$18,094,329 $50.21 170
2020 Q1 17,995,979 $926,515,655 -$30,943,599 $51.43 149
2019 Q4 18,399,795 $1,136,590,687 +$22,032,008 $61.78 164
2019 Q3 17,861,614 $1,073,120,730 +$8,901,782 $60.08 167
2019 Q2 17,638,045 $1,488,131,123 +$13,069,601 $84.38 190
2019 Q1 17,795,931 $1,699,801,094 +$94,812,353 $95.52 193
2018 Q4 16,781,732 $1,188,573,975 +$6,536,076 $70.83 178
2018 Q3 16,592,892 $1,418,186,710 +$116,744,597 $85.46 191
2018 Q2 15,070,342 $1,746,501,438 +$46,101,568 $115.90 184
2018 Q1 14,655,214 $1,185,803,587 +$58,960,340 $80.91 175
2017 Q4 14,015,489 $822,445,465 +$75,245,516 $58.68 139
2017 Q3 12,760,409 $597,075,030 +$18,418,324 $46.80 119
2017 Q2 12,613,190 $453,852,988 -$5,672,600 $35.98 117
2017 Q1 12,844,477 $395,608,591 +$44,282,089 $30.80 122
2016 Q4 13,270,111 $444,423,457 +$17,779,306 $33.50 144
2016 Q3 13,117,480 $348,994,653 +$1,167,845 $26.61 133
2016 Q2 13,405,064 $295,579,870 -$1,422,350 $22.05 125
2016 Q1 14,225,742 $417,749,732 -$10,132,948 $29.37 149
2015 Q4 14,626,888 $483,060,372 -$21,919,941 $33.02 132
2015 Q3 14,527,277 $525,046,889 +$40,323,740 $36.14 136
2015 Q2 13,682,206 $615,100,034 +$77,837,292 $44.99 127
2015 Q1 12,260,874 $375,856,987 +$45,292,958 $30.62 113
2014 Q4 10,416,117 $529,519,559 +$30,310,175 $50.85 119
2014 Q3 9,993,001 $395,400,426 +$64,363,143 $39.57 109
2014 Q2 8,107,805 $348,975,660 +$52,845,612 $43.07 94
2014 Q1 8,425,980 $336,790,708 +$157,617,069 $39.99 77